Sanara Medtech Inc (SMTI) - Total Liabilities
Based on the latest financial reports, Sanara Medtech Inc (SMTI) has total liabilities worth $67.01 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SMTI strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Sanara Medtech Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Sanara Medtech Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sanara Medtech Inc total assets.
Sanara Medtech Inc Competitors by Total Liabilities
The table below lists competitors of Sanara Medtech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HealWELL AI Inc.
TO:AIDX
|
Canada | CA$165.53 Million |
|
Mega Uranium Ltd.
TO:MGA
|
Canada | CA$34.20 Million |
|
Tai-Saw Technology Co Ltd
TWO:3221
|
Taiwan | NT$934.10 Million |
|
Enad Global 7 AB
ST:EG7
|
Sweden | Skr1.09 Billion |
|
AGV Products Corp
TW:1217
|
Taiwan | NT$7.35 Billion |
|
Westwood Holdings Group Inc
NYSE:WHG
|
USA | $24.31 Million |
|
Michlol Finance Ltd
TA:MCLL
|
Israel | ILA1.79 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Sanara Medtech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SMTI net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 11.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sanara Medtech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sanara Medtech Inc (1999–2025)
The table below shows the annual total liabilities of Sanara Medtech Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $67.01 Million | +36.26% |
| 2024-12-31 | $49.18 Million | +67.95% |
| 2023-12-31 | $29.28 Million | +51.61% |
| 2022-12-31 | $19.32 Million | +209.32% |
| 2021-12-31 | $6.24 Million | +56.66% |
| 2020-12-31 | $3.99 Million | -15.64% |
| 2019-12-31 | $4.72 Million | +144.81% |
| 2018-12-31 | $1.93 Million | -8.76% |
| 2017-12-31 | $2.12 Million | -18.46% |
| 2016-12-31 | $2.59 Million | -2.58% |
| 2015-12-31 | $2.66 Million | +14.60% |
| 2014-12-31 | $2.32 Million | -32.56% |
| 2013-12-31 | $3.45 Million | -33.73% |
| 2012-12-31 | $5.20 Million | -32.41% |
| 2011-12-31 | $7.69 Million | +96.51% |
| 2010-12-31 | $3.91 Million | +59.28% |
| 2009-12-31 | $2.46 Million | +419.61% |
| 2008-12-31 | $472.97K | -78.69% |
| 2007-12-31 | $2.22 Million | +25.59% |
| 2006-12-31 | $1.77 Million | +95.22% |
| 2005-12-31 | $905.27K | +458.02% |
| 2004-12-31 | $162.23K | -95.44% |
| 2001-12-31 | $3.56 Million | +41.53% |
| 2000-12-31 | $2.52 Million | +37.64% |
| 1999-12-31 | $1.83 Million | -- |
About Sanara Medtech Inc
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and seco… Read more